Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00962000 · ClinicalTrials.gov registry record · NA

Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate

A NA study, sponsored by Vantive Health.

Completed
Registry status
NA
Development phase
42
Enrollment target

NCT00962000: Completed NA study, sponsored by Vantive Health.

NCT00962000 is a NA study that has completed, run by Vantive Health. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00962000, a NA study, has completed, sponsored by Vantive Health.

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target

Study Summary

The purpose of this study is to look at how the dose of dialysis is affected by the rate at which dialysate flows through the dialyzer. The dose of dialysis (Kt/V) will be determined by measuring blood levels of urea at the beginning and end of dialysis at two different dialysate flow rates.

Primary Outcome

The dose of dialysis delivered in a single treatment is commonly expressed in terms of Kt/Vurea, where K is the clearance of urea, t is the treatment time, and V is the urea distribution volume. When urea is removed from a single compartment during dialysis, it is called the "single-pool" Kt/V. Delivered Kt/Vurea was determined from pre-and post-dialysis BUN concentrations measured during the final treatment session of each group (ABAB or BABA).

Interventions

  • OTHER Dialysis Flow Rate Start 600mL/min
  • OTHER Dialysis Flow Rate Start 800mL/min

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2009-09
Est. Completion 2010-06
Phase NA
Vantive Health

15 total trials

What the finished NCT00962000 record still lists

NCT00962000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Dialysis Flow Rate Start 600mL/min is the first listed.

NCT00962000 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00962000 about?

NCT00962000 is a clinical study titled "Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate". The purpose of this study is to look at how the dose of dialysis is affected by the rate at which dialysate flows through the dialyzer. The dose of dialysis (Kt/V) will be determined by measuring blood levels of urea at the beginning and end of dialysis at two different dialysate flow rates.

What is the current status of trial NCT00962000?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2009-09. Estimated completion is 2010-06.

What interventions are being tested in trial NCT00962000?

The interventions under investigation include: Dialysis Flow Rate Start 600mL/min (OTHER), Dialysis Flow Rate Start 800mL/min (OTHER).

Who is sponsoring clinical trial NCT00962000?

This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00962000's enrollment target sits among peer trials

42 1436th of 2000 higher than 555 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00962000, the US trial registry maintained by the National Library of Medicine. NCT00962000 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.